The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
An update on the Phase III LEAP-010 trial evaluating Eisai Lenvima (lenvatinib) plus Merck & Co’s Keytruda (pembrolizumab), as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1, was announced today. 25 August 2023
Germany’s Bayer has announced that Dr Juergen Eckhardt is to be the new head of business development and licensing / open innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. 25 August 2023
New York-based pharma giant Pfizer has secured a European approval for Abrysvo, an innovative vaccine to prevent infection with respiratory syncytial virus (RSV). 25 August 2023
San Franciso, USA-based biotech start-up Cellares, which has coined its own acronym for an out-sourcing organization, “integrated” development and manufacturing organization (IDMO), has secured $255 million in Series C funding led by new investor Koch Disruptive Technologies. 25 August 2023
Danish allergy immunotherapy specialist ALK Abello has posted financial results showing that revenue grew by 11% to 1.14 billion kroner ($165 million) in the second quarter of 2023. 25 August 2023
Switzerland-based Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. 25 August 2023
The trade body for the British pharmaceutical industry has issued a response to a report from the Journal of Royal Society of Medicine, which raised concerns about the Innovative Medicines Fund. 25 August 2023
The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. 24 August 2023
Privately-held Swiss company Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin (nadofaragene firadenovec-vncg). 24 August 2023
Shares in Apellis Pharmaceuticals soared 30.2% to close at $40.04 yesterday after it provided more information regarding the safety of its eye disease product. 24 August 2023
Less than six months after raising $100 million in a Series A financing, neuromedicines company Rapport Therapeutics has added another $150 million to its coffers. 24 August 2023
Swedish contract development and manufacturing organization (CDMO) NorthX Biologics has appointed Janet Hoogstraate as its new chief executive. 24 August 2023
Swiss cancer giant Roche has been forced to put out a statement addressing an “inadvertent” release of data related to its highly-anticipated anti-TIGIT candidate tiragolumab. 24 August 2023
Seattle, USA-based Alpine Immune Sciences, an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer. 24 August 2023